Publications by authors named "Khalid Mezzi"

Claim this Profile
F
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab.
Elias J Jabbour, Hagop M Kantarjian, Nicola Goekbuget, Bijal D Shah, Sabina Chiaretti, Khalid Mezzi

Blood Cancer J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
Takayuki Yoshino, Naushin Hooda, Diana Younan, Kei Muro, Kohei Shitara, Khalid Mezzi

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.
Nicole Gormley, Lola Fashoyin-Aje, Trevan Locke, Joseph M Unger, Richard F Little, Khalid Mezzi

Blood Cancer Discov· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MCL-1 in hematologic malignancies: Rationale and progress.
Andrew H Wei, Andrew W Roberts, Andrew Spencer, Aaron Seth Rosenberg, David Siegel, Khalid Mezzi

Blood Rev· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Thierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, David Siegel, Cara Rosenbaum, Khalid Mezzi

Blood Adv· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly (70 mg/m ) vs twice-weekly (56 mg/m ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.
Philippe Moreau, Keith A Stewart, Meletios Dimopoulos, David Siegel, Thierry Facon, Khalid Mezzi

Cancer Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Adam D Cohen, Noopur Raje, Jessica A Fowler, Khalid Mezzi, Emma C Scott

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Nina Shah, Ajai Chari, Emma Scott, Khalid Mezzi, Saad Z Usmani

Leukemia· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim S Iskander, Khalid Mezzi

Leukemia· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Meletios Dimopoulos, David Siegel, Darrell J White, Ralph Boccia, Karim S Iskander, Khalid Mezzi

Blood· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting.
Robert M Rifkin, Rohan Medhekar, E Susan Amirian, Kathleen M Aguilar, Thomas Wilson, Khalid Mezzi

Ther Adv Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
Andrzej J Jakubowiak, Jeanne M DeCara, Khalid Mezzi

Hematology· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study.
Ajai Chari, Khalid Mezzi, Shao Zhu, Winifred Werther, Diana Felici

BMC Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.
Donna Reece, Kevin Song, Richard LeBlanc, Khalid Mezzi, Ade Olujohungbe

Oncologist· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis